Please download the dossier by clicking on the dossier button x
×

Long lasting drug formulations

  • US 8,877,175 B2
  • Filed: 02/26/2013
  • Issued: 11/04/2014
  • Est. Priority Date: 09/14/2006
  • Status: Expired due to Fees
First Claim
Patent Images

1. A method of treating anemia in a human subject in need over a sustained time period comprising the steps of:

  • (a) providing at least one autologous erythropoietin secreting genetically modified dermal micro-organ that comprises a helper-dependent adenovirus vector comprising the nucleic acid sequence encoding erythropoietin operably linked to one or more regulatory sequences, wherein said nucleic acid comprises SEQ ID NO;

    11,(b) determining the erythropoietin secretion levels of the at least one genetically modified dermal micro-organ in step (a) in vitro,(c) implanting the autologous genetically modified dermal micro-organ of step (b) in said human subject at an effective dosage at a site selected from the group consisting of subcutaneously, subdermally and intradermally,(d) measuring hemoglobin levels in the blood of said human subject from step (c); and

    (e) maintaining hemoglobin levels in said human subject at 9-11 g/dl in at least 50% of the measurements for at least one month, thereby treating anemia in a human subject.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×